Purple Biotech (PPBT) Non-Interest Income (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Non-Interest Income of $89000.0 for Q1 2026, down 80.48% year-over-year from $456000.0 in Q1 2025, and down 99.62% quarter-over-quarter from $23.6 million in Q4 2025.
Purple Biotech (PPBT) Non-Interest Income (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Non-Interest Income for 10 consecutive years, with $89000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Interest Income fell 80.48% year-over-year to $89000.0; the TTM figure through Mar 2026 stood at $26.1 million (up 559.72% YoY), while the FY2025 annual figure was $26.5 million, up 263.0% from the prior year.
- Non-Interest Income fell to $89000.0 in Q1 2026 per PPBT's latest filing, from $23.6 million in the prior quarter.
- Across five years, Non-Interest Income topped out at $23.6 million in Q4 2025 and bottomed at $89000.0 in Q1 2026.
- Historically, Non-Interest Income has averaged $4.4 million across 5 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Interest Income tumbled 91.46% — and 2025, when it surged 5596.87%.
- Purple Biotech's Non-Interest Income stood at $6.0 million in 2022, then decreased by 19.59% to $4.9 million in 2023, then sank by 91.46% to $415000.0 in 2024, then soared by 5596.87% to $23.6 million in 2025, then sank by 99.62% to $89000.0 in 2026.
- Business Quant data shows PPBT's Non-Interest Income at $89000.0 in Q1 2026, $23.6 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Interest Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,000.00 |
| Dec 31, 2025 | 23.64 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 456,000.00 |
| Dec 31, 2024 | 415,000.00 |
| Sep 30, 2024 | 668,000.00 |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | 3.80 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | 5.16 Mn |
| Mar 31, 2023 | 4.90 Mn |
| Dec 31, 2022 | 6.04 Mn |
| Sep 30, 2022 | 4.85 Mn |
| Jun 30, 2022 | 3.57 Mn |
| Mar 31, 2022 | 7.32 Mn |
| Dec 31, 2021 | 8.26 Mn |
| Sep 30, 2021 | 3.15 Mn |
| Jun 30, 2021 | 3.64 Mn |